** Rare disease-focused biopharmaceutical company Zevra Therapeutics' ZVRA.O shares up ~2.57% at $9.18 premarket
** H.C. Wainwright initiates ZVRA coverage with "buy" rating, says stocks remains undervalued
** Brokerage says the co is now positioned to reward investors as a leading rare disease company with commercial and development expertise
** Sets PT at $26, a ~190.5% upside to stock's last close
** All of eight brokerages rate the stock "buy" or higher; their median PT is $25 - LSEG
** As of last close, stock up ~7.3% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。